Oxygen therapy developer Aviv Scientific completed a $40m series B round led by Danel while drug delivery system developer Credence raised almost as much.

Funding Medical services group Danel led a $40m series B round yesterday for Aviv Scientific, an Israel-based developer of oxygen therapy treatments to address age-related cognitive decline. The round included the deep technology-focused Deep Insight Fund and although Aviv has not revealed details of past funding, its technology stems from a partnership with Sagol Center,…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.